Overview

SLV-154 Treatment of Metastatic Solid Tumors

Status:
RECRUITING
Trial end date:
2027-04-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-154 across a range of dose levels when administered to subjects with metastatic solid tumors.
Phase:
PHASE1
Details
Lead Sponsor:
Solve Therapeutics